Skip to main content Back to Top


Buprenorphine Sublingual Tablets

Products Affected - Description

    • Buprenorphine sublingual tablet, Teva, 2 mg, 30 count, NDC 00093-5378-56
    • Buprenorphine sublingual tablet, Teva, 8 mg, 30 count, NDC 00093-5379-56

Reason for the Shortage

    • Teva could not provide a reason for the shortage.
    • Akorn acquired Hi-Tech Pharmacal in 2014.

Available Products

    • Buprenorphine sublingual tablet, Akorn, 2 mg, 30 count, NDC 50383-0930-93
    • Buprenorphine sublingual tablet, Akorn, 8 mg, 30 count, NDC 50383-0924-93
    • Buprenorphine sublingual tablet, Roxane, 2 mg, 30 count, NDC 00054-0176-13
    • Buprenorphine sublingual tablet, Roxane, 8 mg, 30 count, NDC 00054-0177-13

Estimated Resupply Dates

    • Teva has buprenorphine 2 mg and 8 mg sublingual tablets temporarily unavailable and the company cannot estimate a release date.
    • Akorn and Roxane have had product available for several months.


Updated May 26, 2016 by Leslie Jensen, PharmD, Drug Information Specialist. Created June 18, 2013 by Michelle Wheeler, PharmD, Drug Information Specialist. Copyright 2017, Drug Information Service, University of Utah, Salt Lake City, UT.



Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.